A technology evaluation of the atypical use of a CPP-containing peptide in the formulation and performance of a clinical botulinum toxin product
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A technology evaluation of the atypical use of a CPP-containing peptide in the formulation and performance of a clinical botulinum toxin product
Authors
Keywords
-
Journal
Expert Opinion on Drug Delivery
Volume 20, Issue 9, Pages 1157-1166
Publisher
Informa UK Limited
Online
2023-10-17
DOI
10.1080/17425247.2023.2251399
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1
- (2023) Jessica Stoodley et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials
- (2023) Conor J. Gallagher et al. Toxins
- Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies
- (2022) Myrsini Chamakioti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines
- (2022) John H Joseph et al. Aesthetic Surgery Journal
- Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials
- (2022) Xue Li et al. AESTHETIC PLASTIC SURGERY
- A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia
- (2021) Joseph Jankovic et al. TOXICON
- New generation of cell‐penetrating peptides: Functionality and potential clinical application
- (2021) Siegmund Reissmann et al. JOURNAL OF PEPTIDE SCIENCE
- Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A
- (2021) Nowell Solish et al. DRUGS
- Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy
- (2020) Linxiang Yin et al. PLOS BIOLOGY
- Cell-Penetrating Peptides in Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical Application
- (2020) Jing Xie et al. Frontiers in Pharmacology
- DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines
- (2020) Sabrina G. Fabi et al. DERMATOLOGIC SURGERY
- A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines
- (2020) Jeremy B. Green et al. DERMATOLOGIC SURGERY
- Status update in the use of cell-penetrating peptides for the delivery of macromolecular therapeutics
- (2020) Kaido Kurrikoff et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Cell-penetrating peptides in oncologic pharmacotherapy: A review
- (2020) Nuno Vale et al. PHARMACOLOGICAL RESEARCH
- The TAT Protein Transduction Domain as an Intra-Articular Drug Delivery Technology
- (2020) Sarah E. Mailhiot et al. Cartilage
- Special Delivery: Potential Mechanisms of Botulinum Neurotoxin Uptake and Trafficking within Motor Nerve Terminals
- (2020) Brittany M. Winner et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Stabilizing effect of RTP004 on nonspecific surface adsorption in drug product manufacturing of daxibotulinumtoxinA (DAXI)
- (2019) Tyson Smyth et al. TOXICON
- Novel peptide excipient RTP004 enhances the binding of botulinum neurotoxin type A cell binding domain HC to rat brain synaptosomes
- (2019) Jasmin Weisemann et al. TOXICON
- Revance's novel peptide excipient, RTP004, and its role in stabilizing daxibotulinumtoxinA (DAXI) against aggregation
- (2019) Reza Malmirchegini et al. TOXICON
- Nonclinical overview of daxibotulinumtoxinA for injection to support registration for human use
- (2019) Gregg Prawdzik et al. TOXICON
- Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies
- (2019) Justine Habault et al. MOLECULES
- DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)
- (2019) Vince Bertucci et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Considerations on the Rational Design of Covalently Conjugated Cell-Penetrating Peptides (CPPs) for Intracellular Delivery of Proteins: A Guide to CPP Selection Using Glucarpidase as the Model Cargo Molecule
- (2019) Behzadipour et al. MOLECULES
- DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines
- (2019) Jean D. Carruthers et al. PLASTIC AND RECONSTRUCTIVE SURGERY
- AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients
- (2018) Malgorzata Field et al. Toxins
- Overcoming cellular barriers for RNA therapeutics
- (2017) Steven F Dowdy NATURE BIOTECHNOLOGY
- Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology
- (2017) Marco Pirazzini et al. PHARMACOLOGICAL REVIEWS
- Cell-Penetrating Peptides: From Basic Research to Clinics
- (2017) Giulia Guidotti et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Enhancing Endosomal Escape for Intracellular Delivery of Macromolecular Biologic Therapeutics
- (2016) Peter Lönn et al. Scientific Reports
- Safety and Efficacy of RT002, an Injectable Botulinum Toxin Type A, for Treating Glabellar Lines
- (2015) Enrique Garcia-Murray et al. DERMATOLOGIC SURGERY
- Cationic PTD/CPP-mediated macromolecular delivery: charging into the cell
- (2015) Peter Lönn et al. Expert Opinion on Drug Delivery
- Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them
- (2015) Mark Hallett TOXICON
- Low molecular weight protamine (LMWP): A nontoxic protamine substitute and an effective cell-penetrating peptide
- (2014) Huining He et al. JOURNAL OF CONTROLLED RELEASE
- Everything You Always Wanted to Know About CADY-Mediated siRNA Delivery* (* But Afraid to Ask)
- (2013) Karidia Konate et al. CURRENT PHARMACEUTICAL DESIGN
- Multicenter, Randomized, Phase III Study of a Single Dose of IncobotulinumtoxinA, Free from Complexing Proteins, in the Treatment of Glabellar Frown Lines
- (2013) Alastair Carruthers et al. DERMATOLOGIC SURGERY
- A Randomized, Placebo-Controlled, Double-Blind Phase III Trial Investigating the Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines Using a Stringent Composite Endpoint
- (2013) C. William Hanke et al. DERMATOLOGIC SURGERY
- Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery
- (2013) Feihu Wang et al. JOURNAL OF CONTROLLED RELEASE
- Polyproline-II Helix in Proteins: Structure and Function
- (2013) Alexei A. Adzhubei et al. JOURNAL OF MOLECULAR BIOLOGY
- Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®
- (2013) Jürgen Frevert Drugs in research & development
- Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia
- (2011) Cynthia L. Comella et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Characterization of diffusion and duration of action of a new botulinum toxin type A formulation
- (2011) Hongran F. Stone et al. TOXICON
- Happy birthday cell penetrating peptides: Already 20 years
- (2010) Robert Brasseur et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- Botulinum toxin
- (2010) PK Nigam et al. INDIAN JOURNAL OF DERMATOLOGY
- Randomized, Placebo-Controlled Study of a New Botulinum Toxin Type A for Treatment of Glabellar Lines
- (2009) Fredric Brandt et al. DERMATOLOGIC SURGERY
- Evaluation of Variable-Dose Treatment with a New U.S. Botulinum Toxin Type A (Dysport) for Correction of Moderate to Severe Glabellar Lines: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- (2009) Michael A. C. Kane et al. PLASTIC AND RECONSTRUCTIVE SURGERY
- Peptide-Based Nanoparticle for Ex Vivo and In Vivo Dug Delivery
- (2008) Laurence Crombez et al. CURRENT PHARMACEUTICAL DESIGN
- Live-cell analysis of cell penetration ability and toxicity of oligo-arginines
- (2007) Gisela Tünnemann et al. JOURNAL OF PEPTIDE SCIENCE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started